A crucial step in the drug development process is pharmacovigilance, which assists in identifying the adverse event profile of any medication. Years after the WHO International Drug Monitoring Program was launched, the Indian government launched the Pharmacovigilance Programme of India (PvPI) in 2010. PvPI’s primary purpose is to monitor the Effectively manage adverse drug reactions (ADR) by establishing a number of Adverse Drug Reaction Monitoring Centers (AMC) throughout India and hiring staff with the necessary skills. PvPI has been crucial in raising healthcare professionals (HCPs) knowledge of the significance and procedure for reporting Adverse Drug Reactions (ADRs), which has resulted in a multiplication of ADR reporting. The Pharmacovigilance Program of India (PvPI) is a key player in compiling information about drug safety and entering it into the WHO database. PvPI satisfies the WHO minimal standards for any operational national pharmacovigilance program. Under PvPI, the national coordinating center is the Indian Pharmacopoeia Commission (IPC).When a medicine is noxious, unintended, and occurs at doses normally used in man, an adverse drug reaction (ADR) results.